CD19 and neoplasm: Strategies to improve tumor cell killing by CD19 antibodies include antibody-drug conjugates (ADC) that deliver and release cytotoxic agents [89], T cell recruitment using the bispecific T cell engager (BiTE) molecule blinatumomab and CAR T cell products [90,91], and engineering the CD19 antibody Fc domain to overcome limitations of native CD19 antibodies (Table 1) [92].